Literature DB >> 17066251

Intramembrane receptor-receptor interactions: a novel principle in molecular medicine.

K Fuxe1, M Canals, M Torvinen, D Marcellino, A Terasmaa, S Genedani, G Leo, D Guidolin, Z Diaz-Cabiale, A Rivera, L Lundstrom, U Langel, J Narvaez, S Tanganelli, C Lluis, S Ferré, A Woods, R Franco, L F Agnati.   

Abstract

In 1980/81 Agnati and Fuxe introduced the concept of intramembrane receptor-receptor interactions and presented the first experimental observations for their existence in crude membrane preparations. The second step was their introduction of the receptor mosaic hypothesis of the engram in 1982. The third step was their proposal that the existence of intramembrane receptor-receptor interactions made possible the integration of synaptic (WT) and extrasynaptic (VT) signals. With the discovery of the intramembrane receptor-receptor interactions with the likely formation of receptor aggregates of multiple receptors, so called receptor mosaics, the entire decoding process becomes a branched process already at the receptor level in the surface membrane. Recent developments indicate the relevance of cooperativity in intramembrane receptor-receptor interactions namely the presence of regulated cooperativity via receptor-receptor interactions in receptor mosaics (RM) built up of the same type of receptor (homo-oligomers) or of subtypes of the same receptor (RM type1). The receptor-receptor interactions will to a large extent determine the various conformational states of the receptors and their operation will be dependent on the receptor composition (stoichiometry), the spatial organization (topography) and order of receptor activation in the RM. The biochemical and functional integrative implications of the receptor-receptor interactions are outlined and long-lived heteromeric receptor complexes with frozen RM in various nerve cell systems may play an essential role in learning, memory and retrieval processes. Intramembrane receptor-receptor interactions in the brain have given rise to novel strategies for treatment of Parkinson's disease (A2A and mGluR5 receptor antagonists), schizophrenia (A2A and mGluR5 agonists) and depression (galanin receptor antagonists). The A2A/D2, A2A/D3 and A2A/mGluR5 heteromers and heteromeric complexes with their possible participation in different types of RM are described in detail, especially in the cortico-striatal glutamate synapse and its extrasynaptic components, together with a postulated existence of A2A/D4 heteromers. Finally, the impact of intramembrane receptor-receptor interactions in molecular medicine is discussed outside the brain with focus on the endocrine, the cardiovascular and the immune systems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17066251     DOI: 10.1007/s00702-006-0589-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  186 in total

Review 1.  Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function.

Authors:  Stephane Angers; Ali Salahpour; Michel Bouvier
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

2.  The angiotensin II AT2 receptor is an AT1 receptor antagonist.

Authors:  S AbdAlla; H Lother; A M Abdel-tawab; U Quitterer
Journal:  J Biol Chem       Date:  2001-08-15       Impact factor: 5.157

3.  Dopamine D2 receptor dimer formation: evidence from ligand binding.

Authors:  D Armstrong; P G Strange
Journal:  J Biol Chem       Date:  2001-02-23       Impact factor: 5.157

Review 4.  Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.

Authors:  Michael A Schwarzschild; Kui Xu; Emin Oztas; Jacobus P Petzer; Kay Castagnoli; Neal Castagnoli; Jiang-Fan Chen
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

Review 5.  Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease.

Authors:  K Fuxe; L F Agnati; K Jacobsen; J Hillion; M Canals; M Torvinen; B Tinner-Staines; W Staines; D Rosin; A Terasmaa; P Popoli; G Leo; V Vergoni; C Lluis; F Ciruela; R Franco; S Ferré
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

Review 6.  Receptor-receptor interactions as an integrative mechanism in nerve cells.

Authors:  M Zoli; L F Agnati; P B Hedlund; X M Li; S Ferré; K Fuxe
Journal:  Mol Neurobiol       Date:  1993 Fall-Winter       Impact factor: 5.590

Review 7.  The receptor mosaic hypothesis of the engram: possible relevance of Boolean network modeling.

Authors:  M Zoli; D Guidolin; K Fuxe; L F Agnati
Journal:  Int J Neural Syst       Date:  1996-09       Impact factor: 5.866

8.  Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats.

Authors:  A E Pollack; J S Fink
Journal:  Brain Res       Date:  1996-12-16       Impact factor: 3.252

9.  Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal.

Authors:  Samuel P Lee; Christopher H So; Asim J Rashid; George Varghese; Regina Cheng; A José Lança; Brian F O'Dowd; Susan R George
Journal:  J Biol Chem       Date:  2004-05-24       Impact factor: 5.157

10.  Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer.

Authors:  Meritxell Canals; Daniel Marcellino; Francesca Fanelli; Francisco Ciruela; Piero de Benedetti; Steven R Goldberg; Kim Neve; Kjell Fuxe; Luigi F Agnati; Amina S Woods; Sergi Ferré; Carme Lluis; Michel Bouvier; Rafael Franco
Journal:  J Biol Chem       Date:  2003-08-21       Impact factor: 5.157

View more
  35 in total

1.  On the origin of the triplet puzzle of homologies in receptor heteromers: immunoglobulin triplets in different types of receptors.

Authors:  Alexander O Tarakanov; Kjell G Fuxe; Dasiel O Borroto-Escuela
Journal:  J Mol Neurosci       Date:  2011-09-20       Impact factor: 3.444

Review 2.  On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers.

Authors:  Luigi F Agnati; Diego Guidolin; Jean Pierre Vilardaga; Francisco Ciruela; Kjell Fuxe
Journal:  J Recept Signal Transduct Res       Date:  2010-10       Impact factor: 2.092

Review 3.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

4.  Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics.

Authors:  Susanne Koschatzky; Nuska Tschammer; Peter Gmeiner
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

5.  Possible role of receptor heteromers in multiple sclerosis.

Authors:  A O Tarakanov; K G Fuxe; L F Agnati; L B Goncharova
Journal:  J Neural Transm (Vienna)       Date:  2009-02-20       Impact factor: 3.575

Review 6.  Fluorescent and bioluminescent protein-fragment complementation assays in the study of G protein-coupled receptor oligomerization and signaling.

Authors:  Pierre-Alexandre Vidi; Val J Watts
Journal:  Mol Pharmacol       Date:  2009-01-13       Impact factor: 4.436

7.  Integrin triplets of marine sponges in human brain receptor heteromers.

Authors:  Alexander O Tarakanov; Kjell G Fuxe; Dasiel O Borroto-Escuela
Journal:  J Mol Neurosci       Date:  2012-05-10       Impact factor: 3.444

Review 8.  The concept of allosteric interaction and its consequences for the chemistry of the brain.

Authors:  Jean-Pierre Changeux
Journal:  J Biol Chem       Date:  2013-07-22       Impact factor: 5.157

9.  Wiring and volume transmission in rat amygdala. Implications for fear and anxiety.

Authors:  Miguel Pérez de la Mora; Kirsten X Jacobsen; Minerva Crespo-Ramírez; Candy Flores-Gracia; Kjell Fuxe
Journal:  Neurochem Res       Date:  2008-05-13       Impact factor: 3.996

10.  FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity.

Authors:  Marc Flajolet; Zhongfeng Wang; Marie Futter; Weixing Shen; Nina Nuangchamnong; Jacob Bendor; Iwona Wallach; Angus C Nairn; D James Surmeier; Paul Greengard
Journal:  Nat Neurosci       Date:  2008-10-26       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.